Biotech News
Related news
OCSOculis2026-04-20 08:00 EST
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
OCSOculis2026-05-29 19:06 EST
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
OCULOcular Therapeutix2026-06-04 11:00 EST
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
MGTXMeiraGTx2026-04-14 12:30 EST
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
SGHTSight Sciences2026-04-29 20:05 EST
Sight Sciences to Present at Two Upcoming Investor Conferences
OCULOcular Therapeutix2026-04-01 11:00 EST
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
OKYOOKYO Pharma2026-07-21 13:00 EST
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
LCTXLineage Cell Therapeutics2026-07-06 12:00 EST
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
IRIXIRIDEX2026-06-09 20:05 EST
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
PRQRProQR Therapeutics2026-05-11 12:00 EST
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-08-06 20:05 EST
Oculis Reports Q2 2026 Financial Results and Provides Company Update
OCSOculis2026-08-03 08:00 EST
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
OCSOculis2026-07-08 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Stock data
- Close
- 12.38 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States